ADx receives funding from Bill Gates for developing blood biomarkers

Together with Douglas Galasko, M.D. University of California at San Diego,US, ADx has been granted $375,000 by the Alzheimer Drug Discovery Foundation (ADDF). This foundation has been appointed to select the blood biomarker projects that will be funded with the donation of Bill Gates.

The focus of this particular project will be on a special form of tau and neurofilament light (NfL) in blood.

Neurofibrillary tangles, consisting of the tau protein, represent one of the two major pathological hallmarks of Alzheimer’s disease. Changes in NfL levels, a protein of the neuronal cytoskeleton, is a promising biomarker for several neurodegenerative diseases. This project aims to develop a test for Alzheimer’s disease by measuring tau and NfL in blood. Dr. Galasko and researchers at ADx NeuroSciences are developing these tests using a highly sensitive technology called single molecule immunoassay (Simoa), which can detect proteins at very low concentrations in blood. These tests will pave the way for early disease diagnosis.